In addition to the following abstracts you may wish to visit Lori Majestic's web site which includes results of her patient survey showing weight gain in prolactinoma patients.
NLM CIT. ID: 98331482
TITLE: Increased body weight associated with prolactin secreting pituitary
adenomas: weight loss with normalization of prolactin levels.
AUTHORS: Greenman Y; Tordjman K; Stern N
AUTHOR AFFILIATION:
Institute of Endocrinology, Tel Aviv-Elias Sourasky Medical Center,
Israel.
PUBLICATION TYPES:
JOURNAL ARTICLE
LANGUAGES:
Eng
REGISTRY NUMBERS:
0 (Hormone Antagonists)
25614-03-3 (Bromocriptine)
9002-62-4 (Prolactin)
ABSTRACT:
OBJECTIVE: Hyperprolactinaemia in humans may be associated with a high
prevalence of obesity but the nature of this link is poorly defined.
The aim of this study was to establish the relationship between
hyperprolactinaemia and body weight in patients with prolactin-
secreting pituitary tumours. DESIGN: We conducted a retrospective
study of prolactinoma patients treated at the Endocrine Institute of
the Tel Aviv Medical Center, Israel, during the period 1989-1996.
Patients with clinically non-functioning pituitary macroadenomas
(NFA) served as the control group. Data on demographic parameters,
body weight before and during treatment, clinical presentation
including history of weight fluctuations, tumour size as measured by
computed tomography or magnetic resonance imaging, modalities and
response to treatment, and pituitary function before and during
treatment were recorded from medical files. PATIENTS: Forty-two
patients with prolactinomas (PR) and 36 patients with clinically
non-functioning macroadenomas (NFA) comprised the study population.
RESULTS: Mean weight was 93 +/- 3.4 kg and 78 +/- 2.7 kg in male
patients with PR and NFA respectively (P = 0.0007). Recent weight
gain (8 to 22 kg) was a presenting symptom in 13 PR patients, whereas
only one NFA patient had this clinical presentation (P = 0.001).
Seventeen PR patients lost weight (mean change -8.3 +/- 1.5 kg, range
-2-28 kg), during prolactin lowering therapy, 11 of whom had entirely
normalized prolactin levels. Fourteen of the 18 patients who did not
lose weight still had elevated prolactin levels (P = 0.01). Weight
loss in patients with PR could not be attributed to altered pituitary
function nor to compression of the third ventricle. In contrast to
PR, no significant weight loss was observed in NFA patients.
CONCLUSION: Weight gain and elevated body weight are frequently
associated with prolactinomas regardless of a mass effect on the
hypothalamus or pituitary function. In this series, weight loss was
recorded in 70% of prolactinomas patients and in 90% of male patients
who normalized their prolactin levels. We propose the inclusion of
hyperprolactinaemia in the differential diagnosis of endocrine
obesity and weight gain.
MAIN MESH HEADINGS:
Hyperprolactinemia/*etiology
Pituitary Neoplasms/*complications
Prolactinoma/*complications
Weight Gain/*drug effects
ADDITIONAL MESH HEADINGS:
Adult
Bromocriptine/therapeutic use
Female
Hormone Antagonists/therapeutic use
Human
Hyperprolactinemia/drug therapy
Male
Middle Age
Prolactin/antagonists & inhibitors
Regression Analysis
Retrospective Studies
NLM PUBMED CIT. ID:
9666865
SOURCE: Clin Endocrinol (Oxf) 1998 May;48(5):547-53
NLM CIT. ID: 95140824
TITLE: Endocrine and psychological evaluation of women with recent weight
gain.
AUTHORS: Ferreira MF; Sobrinho LG; Pires JS; Silva ME
Santos MA; Sousa MF
AUTHOR AFFILIATION:
Servico de Endocrinologia, Instituto Portugues de Oncologia, Lisboa.
PUBLICATION TYPES:
CLINICAL TRIAL
CONTROLLED CLINICAL TRIAL
JOURNAL ARTICLE
LANGUAGES:
Eng
REGISTRY NUMBERS:
0 (Gastrins)
0 (Hormones)
11061-68-0 (Insulin)
50-23-7 (Hydrocortisone)
9002-62-4 (Prolactin)
ABSTRACT:
A group of 13 consecutive regularly menstruating women who gained at
least 5 kg the previous year (Group I) was compared to a control
group of similar age, parity, and social class (Group II). The two
groups were similar in estimated and observed food intakes; pre- and
postprandial gastrin levels; hourly 24-h profiles of cortisol and
insulin; urinary cortisol and 17-hydroxycorticosteroids. Group I had
higher serum prolactin concentrations at all times than Group II
(mean values 14.60 micrograms/l vs. 8.84 micrograms/l; p = .0121).
Galactorrhea was observed in 5 women from Group I and in none of the
women from Group II (p < .05). Group I also differed from Group II in
a higher incidence of meaningful life-events the year preceding the
study, higher prevalence of sexual dysfunction (9/13 vs. 4/13; p <
.01) and higher indexes (p < .05) of several parameters in the MMPI
and SCL 90. Median serum cortisol and prolactin concentrations were
negatively correlated, both in Group I (R = -.669; p = .012) and in
the whole sample (R = -.453; p = .0298). It is suggested that the
rapid weight gain is part of a neuroendocrine response to
environmental stimuli also characterized by hyperprolactinemia. The
significant negative correlation between serum prolactin and cortisol
indicates that this response differs from, and is possibly an
alternative to, the sympathoadrenal "stress" response.
MAIN MESH HEADINGS:
Hormones/*blood
Obesity/*blood
Psychophysiologic Disorders/*blood
Stress, Psychological/*complications
Weight Gain/*physiology
ADDITIONAL MESH HEADINGS:
Adult
Energy Intake/physiology
Female
Food Habits/psychology
Gastrins/blood
Human
Hydrocortisone/blood
Insulin/blood
Life Change Events
Obesity/psychology
Personality Assessment
Pituitary Neoplasms/blood
Pituitary Neoplasms/psychology
Prolactin/blood
Prolactinoma/blood
Prolactinoma/psychology
Pseudopregnancy/blood
Pseudopregnancy/psychology
Psychophysiologic Disorders/psychology
Reference Values
Stress, Psychological/blood
NLM PUBMED CIT. ID:
7838902
SOURCE: Psychoneuroendocrinology 1995;20(1):53-63
NLM CIT. ID: 92067400
TITLE: Prolactinoma and body weight: a retrospective study.
AUTHORS: Creemers LB; Zelissen PM; van 't Verlaat JW
Koppeschaar HP
AUTHOR AFFILIATION:
Department of Endocrinology, University Hospital, Utrecht, The
Netherlands.
PUBLICATION TYPES:
JOURNAL ARTICLE
LANGUAGES:
Eng
REGISTRY NUMBERS:
9002-62-4 (Prolactin)
ABSTRACT:
Body weight and weight history in association with hormone levels were
studied retrospectively in 47 patients with prolactinoma;
macroprolactinoma was diagnosed in 36, microprolactinoma in 11
patients. At the time of diagnosis a weight history could be traced
in 14 patients, 9 patients having gained weight (11.8 +/- 2 kg), 1
with a weight loss of 5 kg, and 4 reporting unaltered body weight.
Body weight and Body Mass Index before treatment were 83 +/- 2.4 kg
and 27.3 +/- 0.6 kg/m2, respectively. In the male patients the
prevalence of BMI greater than or equal to 25 was greater than in the
average Dutch male population (p less than 0.001). After 6 months of
treatment, mainly with bromocriptine, patients with macroprolactinoma
had lost 5.5 +/- 1.6% (p less than 0.002) of initial body weight. No
significant weight change occurred in patients with
microprolactinoma. Weight loss did not correlate with degree of
hyperprolactinemia, nor with decrease of prolactin levels during
treatment, in either group of patients. Thyroid or gonadal function
were not associated with weight loss either. It appears that
prolactinoma is associated with a higher frequency of overweight, as
far as patients with macroprolactinoma are concerned.
MAIN MESH HEADINGS:
*Body Weight
Pituitary Neoplasms/*pathology
Prolactinoma/*pathology
ADDITIONAL MESH HEADINGS:
Adolescence
Adult
Aged
Body Mass Index
Female
Human
Male
Middle Age
Pituitary Neoplasms/blood
Pituitary Neoplasms/therapy
Prolactin/blood
Prolactinoma/blood
Prolactinoma/therapy
Reference Values
Retrospective Studies
NLM PUBMED CIT. ID:
1957557
SOURCE: Acta Endocrinol (Copenh) 1991 Oct;125(4):392-6
Return to my Treatment of Prolactinomas page
This Page Last Updated on 9th. July, 2000